Capsule Technology Group
Executive SummaryWindsor, Ontario-based firm will produce EPA-CHOL 700, an EPA/DHA concentrate product for reducing cholesterol at its newly built Mulgrave, Nova Scotia plant. The $ 8 mil. plant was constructed with the help of tax breaks and an interest-free loan from the Canadian government. Wyeth-Canada will market the product in that country pending Canadian marketing approval, Capsule Technology says, estimating sales of $ 13 mil. over the next 12 months.
You may also be interested in...
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, talks in a wide-ranging interview about the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.
Political tensions between Switzerland and the EU have led to concerns about the future status of the only Swiss medtech notified body, SQS. Here’s what SQS board member Daniel Taddeo said about the situation.